Interim Analysis of Randomized Phase II Study of Recombinant Human Epidermal Growth Factor on Oral Mucositis Induced by Intensive Chemotherapy with Stem Cell Transplantation for Hematologic Malignancies
Ji‐Won Kim(Kyungpook National University), Byoung Kook Kim(Seoul National University), Kyung Im Kim(Korea University), Hyun Jung Lee(Yonsei University), Soo‐Mee Bang(Seoul National University), Jong Seok Lee(Korea Institute of Ocean Science and Technology), Byung‐Su Kim(Hallym University Dongtan Sacred Heart Hospital), Sung‐Soo Yoon(Seoul National University Hospital), Seonyang Park(Seoul National University), Inho Kim(Seoul National University), Jung Mi Oh(Seoul National University)
Cited by 1
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
|The Lancet Oncology|2020|401
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
|The Lancet|2023|194